Premarin — Competitive Intelligence Brief

Premarin (Estrogens, Conjugated) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen replacement therapy. Area: Metabolic.

marketed Estrogen replacement therapy Estrogen receptors (nuclear receptors) Metabolic Hormone therapy

Target snapshot

Premarin (Estrogens, Conjugated) — Pfizer. Conjugated estrogens bind to nuclear estrogen receptors in estrogen-responsive tissues, modulating gonadotropin secretion and reducing elevated LH and FSH in postmenopausal women.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Premarin TARGET	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Estradiol vaginal cream	Estradiol vaginal cream	CONRAD	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estrogen vaginal cream	Estrogen vaginal cream	The University of Texas Health Science Center, Houston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha and beta
Premarin vaginal estrogen cream	Premarin vaginal estrogen cream	Medstar Health Research Institute	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Postmenopausal, topical vaginal estrogen cream	Postmenopausal, topical vaginal estrogen cream	The University of Texas Medical Branch, Galveston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen replacement therapy class)

1. Pfizer · 3 drugs in this class
2. CONRAD · 1 drug in this class
3. Mylan Pharmaceuticals Inc · 1 drug in this class
4. University of California, Irvine · 1 drug in this class
5. University of Virginia · 1 drug in this class